<DOC>
	<DOCNO>NCT00087594</DOCNO>
	<brief_summary>This study evaluate safety tolerability PEGASYS plus ribavirin previous intravenous ( iv ) drug user CHC currently enrol methadone maintenance treatment program . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Combination With Copegus ( Ribavirin ) Patients With Chronic Hepatitis C ( CHC ) Enrolled Methadone Maintenance Treatment Program .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>adult patient least 18 year age CHC infection , genotype 1 , 2 , 3 naive treatment CHC infection enrol methadone maintenance program document attendance least 3 month use 2 form contraception study men woman previous treatment CHC infection coinfection human immunodeficiency virus ( HIV ) current use IV illicit drug decompensated cirrhosis woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>